Kalaris Therapeutics, Inc.
Datakwaliteit: 83%
KLRS
Nasdaq
Manufacturing
Chemicals
€ 5,99
▼
€ 0,35
(-5,52%)
Marktkapitalisatie: 137,34 M
Prijs
€ 5,99
Marktkapitalisatie
137,34 M
Dagbereik
€ 5,83 — € 6,64
52-Weeksbereik
€ 2,14 — € 11,88
Volume
60.393
Openen € 6,40
50D / 200D Gem.
€ 8,65
30,76% below
50D / 200D Gem.
€ 6,00
0,20% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -38,57 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-91,47%
Onder sectorgemiddelde (-53,41%)
ROIC-45,49%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio12,89
Interest Coverage-31,98
Waardering
PE (TTM)
-3,16
Onder sectorgemiddelde (-1,48)
P/B Ratio3,28
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -3,2 | -1,5 |
| P/B | 3,3 | 1,6 |
| ROE % | -91,5 | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -43,44 M |
| ROE | -91,47% | ROA | -49,92% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -38,57 M |
| ROIC | -45,49% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 12,89 |
| Interest Coverage | -31,98 | Asset Turnover | N/A |
| Working Capital | 72,12 M | Tangible Book Value | 41,87 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -3,16 | Forward P/E | N/A |
| P/B Ratio | 3,28 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -28,08% | ||
| Market Cap | 137,34 M | Enterprise Value | 94,95 M |
| Per Share | |||
| EPS (Diluted TTM) | -2,85 | Revenue / Share | N/A |
| FCF / Share | -1,68 | OCF / Share | -1,67 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 88,79% |
| SBC-Adj. FCF | -45,12 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -43,44 M | -58,77 M | -190,42 M | -168,71 M | -171,96 M |
| EPS (Diluted) | -2,85 | -11,73 | -1,83 | -2,20 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -46,15 M | -65,44 M | -199,90 M | -171,20 M | -169,82 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 30,75 M | 12,34 M | 133,07 M | 118,87 M | 120,74 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | 398.000,0 | 398.000,0 | 723.000,0 | 189.000,0 |
| Interest Expense | 1,44 M | — | — | — | — |
| Income Tax | 0,0 | 0,0 | -126.000,0 | -265.000,0 | 1,01 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 121,74 M | 118,55 M | 190,80 M | 277,08 M | 286,59 M |
| Total Liabilities | 42,92 M | 5,24 M | 45,02 M | 52,56 M | 61,33 M |
| Shareholders' Equity | 78,81 M | 113,31 M | 145,78 M | 224,52 M | 225,27 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 98,05 M | 118,29 M | 90,12 M | 106,09 M | 201,66 M |
| Current Assets | 118,81 M | 118,55 M | 187,64 M | 243,05 M | 253,35 M |
| Current Liabilities | 9,71 M | 5,24 M | 28,37 M | 24,34 M | 37,85 M |
{"event":"ticker_viewed","properties":{"ticker":"KLRS","listing_kind":"stock","pathname":"/stocks/klrs","exchange":"Nasdaq","country":"US"}}